Seroepidemiology of SARS-CoV-2 in a cohort of pregnant women and their infants in Uganda and Malawi.

Publication date: Mar 01, 2024

Data on SARS-CoV-2 infection in pregnancy and infancy has accumulated throughout the course of the pandemic, though evidence regarding asymptomatic SARS-CoV-2 infection and adverse birth outcomes are scarce. Limited information is available from countries in sub-Saharan Africa (SSA). The pregnant woman and infant COVID in Africa study (PeriCOVID Africa) is a South-South-North partnership involving hospitals and health centres in five countries: Malawi, Uganda, Mozambique, The Gambia, and Kenya. The study leveraged data from three ongoing prospective cohort studies: Preparing for Group B Streptococcal Vaccines (GBS PREPARE), SARS-CoV-2 infection and COVID-19 in women and their infants in Kampala and Mukono (COMAC) and Pregnancy Care Integrating Translational Science Everywhere (PRECISE). In this paper we describe the seroepidemiology of SARS-CoV-2 infection in pregnant women enrolled in sites in Uganda and Malawi, and the impact of SARS-CoV-2 infection on pregnancy and infant outcomes. Seroprevalence of SARS-CoV-2 antibodies in maternal blood, reported as the proportion of seropositive women by study site and wave of COVID-19 within each country. The PeriCOVID study was a prospective mother-infant cohort study that recruited pregnant women at any gestation antenatally or on the day of delivery. Maternal and cord blood samples were tested for SARS-CoV-2 antibodies using Wantai and Euroimmune ELISA. In periCOVID Uganda and Malawi nose and throat swabs for SARS-Cov-2 RT-PCR were obtained. In total, 1379 women were enrolled, giving birth to 1387 infants. Overall, 63% of pregnant women had a SARS-CoV-2 positive serology. Over subsequent waves (delta and omicron), in the absence of vaccination, seropositivity rose from 20% to over 80%. The placental transfer GMR was 1. 7, indicating active placental transfer of anti-spike IgG. There was no association between SARS-CoV-2 antibody positivity and adverse pregnancy or infancy outcomes.

Open Access PDF

Concepts Keywords
Africa Africa
Hospitals Cohort
Pandemic Cov
Pcr Covid
Pregnancy Infant


Type Source Name
disease VO pregnant women
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH adverse birth outcomes
disease IDO blood
disease IDO site
disease IDO country
disease VO nose
disease VO vaccination
disease MESH Infection
disease VO vaccine
disease IDO intervention
disease IDO history
disease IDO process
drug DRUGBANK Ademetionine
disease VO frequency
disease VO population
disease MESH viral infections
disease MESH infectious diseases
disease VO protocol
disease IDO assay
disease MESH asymptomatic infection
disease MESH syndrome
drug DRUGBANK Sparfosic acid
drug DRUGBANK Coenzyme M
drug DRUGBANK Etoperidone
disease MESH co infection
disease MESH malaria
pathway KEGG Malaria
disease MESH complications
disease MESH stillbirth
disease MESH maternal death
disease MESH neonatal death
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH malformations
disease MESH infant death
disease MESH pregnancy outcome
disease MESH asphyxia

Original Article

(Visited 1 times, 1 visits today)